What it sells
AI Operating System for Clinical Development
Business model breakdown
Buyer: who owns the budget?
UnverifiedHeads of biometrics / clinical development at sponsors, with IT, security and quality teams involved.
Trigger: what makes them buy now?
Biometrics capacity limits and trial bottlenecks; claims 30-50% faster progress, >1500 potential trial errors avoided, >$10M potential savings identified.
Workflow: what inputs become what output?
Map one study data, analysis needs and deliverables, automate repetitive biometrics (SDTM, ADaM, TLFs) in connected workflow with human review gates and traceability from SAP to output.
Economics: what it saves and how it charges
UnverifiedNot stated; offers AI-augmented FSP / end-to-end biometrics services plus platform.
Distribution: how it reaches customers
Demo-led (Request a demo / Book a demo); enterprise deploys inside client environment; conference sponsorship.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Spring 2026 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.